Moleculin Biotech (MBRX) Receivables (2018 - 2023)

Moleculin Biotech (MBRX) posted quarterly Receivables of $12000.0 for Q2 2023, down 45.45% quarter-over-quarter from $22000.0 in Q4 2022.

Moleculin Biotech (MBRX) Receivables (2018 - 2023) Analysis & Trends

Moleculin Biotech's Receivables history runs 5 years deep, the most recent figure standing at $12000.0 for Q2 2023.

In Q2 2023, Receivables changed N/A year-over-year to $12000.0; the TTM figure through Jun 2023 stood at $12000.0 (changed N/A YoY), while the FY2022 annual figure was $22000.0, changed N/A from the prior year.
Receivables for Q2 2023 stood at $12000.0, down from $22000.0 in the prior quarter.
The five-year high for Receivables was $316000.0 in Q3 2019, with the low at $1000.0 in Q1 2020.
The 4-year median for Receivables is $12000.0 (2023), against an average of $72400.0.
Peak annual rise in Receivables reached 80.36% in 2019, while the deepest fall reached 80.36% in 2019.
Moleculin Biotech's Receivables stood at $11000.0 in 2019, then sank by 90.91% to $1000.0 in 2020, then soared by 2100.0% to $22000.0 in 2022, then sank by 45.45% to $12000.0 in 2023.
Business Quant data shows MBRX's Receivables at $12000.0 in Q2 2023, $22000.0 in Q4 2022, and $1000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	Moleculin Biotech	3.35 Mn	3.35 Mn	-	-

Download Data